Clinical Trials Logo

Clinical Trial Summary

This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL) including subjects with intermediate-1, intermediate-2, or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).

Clinical Trial Description

NS-018 will be self-administered orally at a dose of 300 mg BID. The BAT will be administered according to manufacturer's instructions and Investigator discretion. Subjects will complete study visits at Screening, Day 1 and Day 15 of Cycle 1, 2, 3, 4, 5, 6 and Day 1 of every cycle thereafter. At these visits, blood/urine sampling, spleen measurements, bone marrow assessments, patient-reported outcome (PRO) assessments, and safety assessments may be performed. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04854096
Study type Interventional
Source NS Pharma, Inc.
Contact NS Pharma, Inc.
Phone 201-986-3860
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2021
Completion date April 24, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Completed NCT01178281 - Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Phase 3
Active, not recruiting NCT00095784 - Decitabine in Treating Patients With Myelofibrosis Phase 2
Recruiting NCT02897297 - Myeloproliferative Neoplastic Diseases Observatory From Brest
Terminated NCT02091752 - A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) Phase 2
Completed NCT01445769 - Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Unknown status NCT01298934 - LBH589 (Panobinostat) for the Treatment of Myelofibrosis Phase 1/Phase 2
Terminated NCT00387426 - Sunitinib in Treating Patients With Idiopathic Myelofibrosis Phase 2
Active, not recruiting NCT02530619 - Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia N/A
Completed NCT01731951 - Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis Phase 2
Recruiting NCT02386800 - CINC424A2X01B Rollover Protocol Phase 4
Completed NCT01371617 - A Phase 2 Study With IPI-926 in Patients With Myelofibrosis Phase 2
Recruiting NCT02251821 - JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Phase 2
Recruiting NCT04446650 - A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Phase 1/Phase 2
Completed NCT01981850 - A Phase 2 Study Of PRM-151 In Participants With Myelofibrosis Phase 2
Withdrawn NCT04283526 - Study of Select Combinations in Adults With Myelofibrosis Phase 1
Withdrawn NCT02584777 - A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis Phase 2
Withdrawn NCT02871323 - Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Phase 1
Withdrawn NCT02528877 - Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Phase 1